Azienda Sanitaria Universitaria Giuliano Isontina — Clinical Trial Site

24 Registered trials

5 Currently recruiting

Organisation

Azienda Sanitaria Universitaria Giuliano Isontina

Location

Trieste, Italy

Identifier

ORG-100041777

Address

Via Costantino Costantinides 2, 34128, Italy

Departments

Cardiology
DAI EMATOLOGIA, ONCOLOGIA E INFETTIVOLOGIA
DAI EMATOLOGIA, ONCOLOGIA E INFETTIVOLOGIA - UOC EMATOLOGIA
Department of Hematology
Dipartimento Cardiovascolare
Hematology
Infectious Diseases
MEDICINE SPECIALISTICHE AREA GIULIANA – CLINICA NEUROLOGICA
N/A
Ophthalmology Clinical Operating Unit
S.C Ematologia
SC CLINICA NEUROLOGICA ASUGI - SS STROKE UNIT
SC Ematologia
SC UCO Ematologia
Struttura Complessa di Pneumologia
Struttura Complessa Ematologia

Clinical trials at this site (24)

Search interface

Evaluaton of ibrutinib therapy for the treatment of autoimmune Hemolytic Anemia in Patients with Chronic Lymphocytic Leukemia/Small Lymphocy… Recruiting

2023-509793-38-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 4 2023-11-24
A study to assess efficacy of citicoline on visual field preservation in patients with glaucoma Recruiting

2022-502273-42-00 Glaucoma 5 2023-11-08
First-line combination of Bcl-2 inhibitor and monoclonal antibody followed by administration of Bcl-2 inhibitor alone or combination of Bcl-… Recruiting

2023-510431-11-00 Chronic Lymphocytic Leukemia 4 2023-07-21
Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3) Recruiting

2022-500587-35-01 Stroke 5 2023-07-06
Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting

2023-510433-29-00 Favorable-intermediate-risk Acute Myeloid Leukemia 5 2020-09-24
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
Consolidation with ADCT-402 (loncastuximab tesirine) after a short course of immunochemotherapy: a phase II study in BTKi-treated (or BTKi i… Ended

2024-511633-35-00 Mantle cell lymphoma 4 2022-03-21
A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr… Ended

2023-504684-16-00 follicular lymphoma (FL) and marginal zone lymphoma (MZ 5 2021-06-05
Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients… Ended

2022-500237-92-00 Newly-diagnosed high-intermediate and high-risk diffuse 5 2021-04-23
Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Ended

2023-503384-41-00 Relapsed or refractory diffuse large B-cell lymphoma (D 5 2020-12-22
A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended

2023-504830-23-00 B-cell Lymphoma 5 2020-12-16
POLAR BEAR Ended

2022-502887-19-00 Diffuse Large B-Cell Lymphoma 5 2020-08-18
Clinical study of ibrutinib and rituximab in untreated marginal zone lymphomas Ended

2023-507886-25-00 Previously untreated and symptomatic patients with hist 4 2019-09-27
Phase II multicenter single arm study to evaluate the efficacy and safety of ibrutinib in combination to rituximab-CHOP followed by ibrutini… Ended

2024-511641-18-00 Diffuse Large B-cell Lymphoma ABC 4 2019-08-01
An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4) Ended

2023-507067-19-00 Autoimmune Cytopenias (warm autoimmune hemolytic anemia 4 2024-05-15
A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous efzofitimod in patients wit… Ended

2023-506039-13-00 pulmonary sarcoidosis 5 2023-04-12
Safety and Tolerability of AC01 in patients with heart failure Ended

2022-500347-20-00 Heart Failure 9 2023-02-23
EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Ended

2023-504832-16-00 DIFFUSE LARGE B CELL LYMPHOMA 4 2023-01-24
Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct) Ended

2022-500363-12-00 SARS CoV-2 (COVID-19) 4 2022-08-24
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) Ended

2022-500881-80-00 Chronic Heart Failure With Reduced Ejection Fraction 5 2021-10-29
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended

2023-506926-35-00 Atherosclerotic cardiovascular disease, chronic kidney 5 2021-09-24
European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (SolidAct) Ended

2022-500385-99-00 SARS-CoV II infection (Coronavirus disease) 5 2021-06-03
A Clinical Trial to Test the Safety, Effect, and Activity of Rilzabrutinib (PRN1008) in Adult and Adolescent Patients with Persistent or Chr… Ended

2023-509401-71-00 Immune Thrombocytopenia (ITP) 5 2021-02-05